Format

Send to

Choose Destination
Clin Pharmacol Ther. 2012 Oct;92(4):431-3. doi: 10.1038/clpt.2012.94. Epub 2012 Aug 22.

Individualization of tamoxifen treatment for breast carcinoma.

Author information

1
Department of Medical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

Abstract

Traditionally, all patients treated with tamoxifen receive a standard dose. A number of studies claimed a clinically relevant impact of cytochrome P450 2D6 (CYP2D6) genotype on outcome, and therefore genotyping before tamoxifen therapy was advocated. Recent data showed that adequate exposure to the active metabolite endoxifen is important and that genotype only partially explains interindividual differences in endoxifen concentrations. Phenotyping approaches, as well as therapeutic drug monitoring (TDM) strategies, are now being tested to individualize tamoxifen treatment.

PMID:
22910442
DOI:
10.1038/clpt.2012.94
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center